Table 1.
Subject | Group | DTI | RT-PCR | Myelin composition |
Age at Necropsy |
---|---|---|---|---|---|
I-319 | CTL | X | X | X | 19 m |
I-318 | CTL | X | X | X | 19 m |
B-301 | CTL | X | X | X | 30 m |
I-262 | CTL | X | X | X | 29 m |
I-371* | MPS | X | X | 20 m | |
I-388* | MPS | X | X | 17 m | |
I-392* | MPS | X | X | 17 m | |
I-393* | MPS | X | X | 17 m | |
I-399 | MPS | X | 21 m | ||
I-272 | MPS | X | X | X | 25 m |
I-266 | MPS | X | X | X | 25 m |
I-267 | MPS | X | X | X | 26 m |
I-265 | MPS | X | X | X | 26 m |
I-394 | MTr | X | X | X | 21 m |
I-400 | MTr | X | X | X | 21 m |
I-402 | MTr | X | X | X | 21 m |
I-413 | MTr | X | X | X | 21 m |
MPS: mucopolysaccharidosis; MTr: MPS I dogs treated with intrathecal recombinant human alpha-l-iduronidase; DTI: diffusion tensor imaging; RT-PCR: reverse transcriptase-polymerase chain reaction.
Dogs that received intra-articular alpha-l-iduronidase are marked with an *.